【摘要】：目的:制備針對EGFR的靶向納米造影劑C225-USPIO,并檢測其標記裸鼠鼻咽癌移植瘤MR成像(MRI)能力。方法:將西妥昔單抗(C225)與USPIO結合成C225-USPIO;檢測造影劑粒徑;選擇EGFR高表達的鼻咽癌SUNE1 5-8F細胞株,接種于12只裸鼠的大腿腹側皮下,待瘤直徑增長至5mm時,隨機分實驗組和對照組各6只,將C225-USPIO或USPIO通過鼠尾靜脈注射,于注射后0、8、24、72 h經磁共振成像儀行T2WI掃描;檢測腫瘤組織內造影劑分布。結果:C225-USPIO粒徑約45～50 nm;MRI示實驗組8 h T2值較0 h略降低(P0.05),24 h顯著降低(P0.05),72 h無明顯改變(P0.05)。對照組8～72 h各時間點T2值與0 h相比無明顯改變(P0.05);注射造影劑72 h后腫瘤組織未見明顯鐵顆粒。結論:C225-USPIO顆粒可通過毛細血管,并能運用于體內磁共振分子成像,可以降低裸鼠移植瘤磁共振T2信號強度,具有一定的特異性和靶向性。
[Abstract]:Aim: to prepare a targeted nano-contrast agent C225 / USPIO for EGFR and to detect its ability to label MR imaging (MRI) of nasopharyngeal carcinoma (NPC) transplantable tumors in nude mice. Methods: cetuximab (C225) was combined with USPIO to form C225 USPIO, and the particle size of contrast agent was detected. SUNE1 5 鈮，

本文編號：2508741